CNS Pharmaceuticals (CNSP) Competitors $0.10 0.00 (-0.60%) Closing price 01/30/2025 04:00 PM EasternExtended Trading$0.10 0.00 (-2.61%) As of 06:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CNSP vs. NXTC, MTEX, FBRX, LSTA, TENX, CARM, ATHE, ALLK, COCP, and SNTIShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include NextCure (NXTC), Mannatech (MTEX), Forte Biosciences (FBRX), Lisata Therapeutics (LSTA), Tenax Therapeutics (TENX), Carisma Therapeutics (CARM), Alterity Therapeutics (ATHE), Allakos (ALLK), Cocrystal Pharma (COCP), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry. CNS Pharmaceuticals vs. NextCure Mannatech Forte Biosciences Lisata Therapeutics Tenax Therapeutics Carisma Therapeutics Alterity Therapeutics Allakos Cocrystal Pharma Senti Biosciences CNS Pharmaceuticals (NASDAQ:CNSP) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Is CNSP or NXTC more profitable? CNS Pharmaceuticals' return on equity of 0.00% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets CNS PharmaceuticalsN/A N/A -515.32% NextCure N/A -62.50%-53.67% Does the MarketBeat Community prefer CNSP or NXTC? NextCure received 32 more outperform votes than CNS Pharmaceuticals when rated by MarketBeat users. However, 71.64% of users gave CNS Pharmaceuticals an outperform vote while only 64.52% of users gave NextCure an outperform vote. CompanyUnderperformOutperformCNS PharmaceuticalsOutperform Votes4871.64% Underperform Votes1928.36% NextCureOutperform Votes8064.52% Underperform Votes4435.48% Do insiders and institutionals hold more shares of CNSP or NXTC? 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 0.1% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 13.3% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, CNSP or NXTC? CNS Pharmaceuticals has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500. Comparatively, NextCure has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Do analysts prefer CNSP or NXTC? CNS Pharmaceuticals presently has a consensus target price of $0.50, indicating a potential upside of 401.00%. NextCure has a consensus target price of $4.00, indicating a potential upside of 400.63%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe CNS Pharmaceuticals is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, CNSP or NXTC? NextCure is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCNS PharmaceuticalsN/AN/A-$18.85M-$74.970.00NextCureN/AN/A-$62.72M-$2.09-0.38 Does the media refer more to CNSP or NXTC? In the previous week, CNS Pharmaceuticals had 2 more articles in the media than NextCure. MarketBeat recorded 5 mentions for CNS Pharmaceuticals and 3 mentions for NextCure. NextCure's average media sentiment score of 0.63 beat CNS Pharmaceuticals' score of 0.36 indicating that NextCure is being referred to more favorably in the news media. Company Overall Sentiment CNS Pharmaceuticals Neutral NextCure Positive SummaryCNS Pharmaceuticals beats NextCure on 8 of the 15 factors compared between the two stocks. Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.74M$6.87B$5.57B$9.17BDividend YieldN/A2.93%5.30%3.99%P/E Ratio0.005.2563.9914.83Price / SalesN/A357.401,199.1381.34Price / CashN/A65.8244.4537.42Price / Book0.005.315.124.72Net Income-$18.85M$125.22M$106.09M$226.19M7 Day PerformanceN/A0.18%0.80%0.50%1 Month PerformanceN/A0.98%3.86%2.13%1 Year PerformanceN/A8.72%26.19%21.21% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals1.8645 of 5 stars$0.10-0.6%$0.50+401.0%-99.2%$5.74MN/A0.005Short Interest ↓Gap DownNXTCNextCure4.7104 of 5 stars$0.81-1.3%$4.00+392.3%-31.7%$22.76MN/A-0.3990Short Interest ↓MTEXMannatech0.4585 of 5 stars$11.86-3.2%N/A+26.5%$22.30M$131.96M-14.64250Analyst ForecastShort Interest ↑News CoverageFBRXForte Biosciences3.9136 of 5 stars$15.24+0.7%$23.58+54.7%+57,726.1%$22.25MN/A-0.945Short Interest ↓Gap UpLSTALisata Therapeutics2.8965 of 5 stars$2.64-1.5%$15.00+468.2%-5.8%$22.15MN/A-1.0530Short Interest ↓TENXTenax Therapeutics2.2037 of 5 stars$6.38-2.4%$16.00+150.8%-51.8%$21.76MN/A0.009CARMCarisma Therapeutics4.3629 of 5 stars$0.51+7.0%$4.94+870.3%-77.3%$21.26M$14.92M-0.3320Short Interest ↓News CoveragePositive NewsATHEAlterity Therapeutics3.0653 of 5 stars$2.91-1.0%$6.00+106.2%+104.0%$21.24MN/A0.0010Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageGap UpALLKAllakos4.4367 of 5 stars$0.24-80.5%$2.00+746.4%-81.9%$21.11MN/A-0.12190Gap DownHigh Trading VolumeCOCPCocrystal Pharma3.7363 of 5 stars$2.06-2.4%$7.00+239.8%+23.6%$20.95MN/A-1.1110Short Interest ↓SNTISenti Biosciences3.3662 of 5 stars$4.52-4.2%$10.00+121.2%-7.7%$20.74M$2.56M-0.294Short Interest ↓ Related Companies and Tools Related Companies NXTC Competitors MTEX Competitors FBRX Competitors LSTA Competitors TENX Competitors CARM Competitors ATHE Competitors ALLK Competitors COCP Competitors SNTI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNSP) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThe #1 Stock for Trump’s Second Term?Imagine how much money you could make if you bought all of the top performing stocks during Trump's second ter...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
